3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
5
Unknown
2
Not yet recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
4
Prostatic Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Advanced Solid Tumor
3
Pancreatic Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Hypoxia
2
Advanced Solid Tumors
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pelvic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Monocytic, Acute
1
Leukemia, Biphenotypic, Acute
1
Interventions
pembrolizumab
20
Carboplatin
14
Cyclophosphamide
12
atezolizumab
11
Paclitaxel
10
Albumin-Bound Paclitaxel
8
Capecitabine
7
Nivolumab
6
130-nm albumin-bound paclitaxel
6
spartalizumab
5
fludarabine
5
Taxes
5
Gemcitabine
5
talazoparib
4
bintrafusp alfa protein, human
4
avelumab
4
Cisplatin
4
sacituzumab govitecan
3
olaparib
3
entinostat
3
Leucovorin
3
Ipilimumab
3
Immunoglobulin G
3
Drug Therapy
3
Doxorubicin
3
Docetaxel
3
Biopsy
3
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
3
trilaciclib
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Triple Negative Breast Neoplasms
×
Injections
×
Clear all
NCT04770272
2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2
Terminated
442 enrolled
42 charts